Meta AnalysisID 6321
芪苈强心胶囊治疗扩张型心肌病的有效性和安全性：一项系统评价与Meta分析
CRD42022297906
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Qili Qiangxin capsule for dilated cardiomyopathy.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6321
- Evidence Id
- 14879
- Core Evidence Id
- 14879
- Source Meta Analysis Id
- 6306
- Herb2 Meta Analysis Id
- HBMA006306
- Crd Id
- CRD42022297906
- Title
- Efficacy and Safety of Qili Qiangxin capsule for dilated cardiomyopathy: A Systematic Review and Meta-Analysis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of Qili Qiangxin capsule for dilated cardiomyopathy.
- Study Type Included
- RCTs of Qili Qiangxin capsule for patients with DCM were strictly included
- Condition Being Studied
- With the improvement of people's living standards, the change of living habits, the aging population, and the changing environment, the risk factors of cardiovascular disease are rising, resulting in the high incidence and mortality of cardiovascular disease. According to the survey, there are about 230 million patients with cardiovascular disease in China, which is growing continuously. It can be imagined that it has increased the burden of prevention and treatment, which has become an urgent problem to be solved in China. Dilated cardiomyopathy (DCM) is the most common cardiomyopathy, which is characterized by unilateral or bilateral ventricular enlargement and decreased systolic function, but there is no overall systolic function damage caused by other load abnormalities (hypertension and valvular disease) or coronary artery (coronary artery) lesions. The etiology can be divided into genetic or nongenetic. For DCM, there is still a lack of effective and specific treatment methods in modern medicine. In addition to medical treatment, there are also cardiac resynchronization treatment and heart transplantation, in order to improve the symptoms of heart failure, prevent complications, prevent or delay the progress of the disease and improve the survival rate of patients
- Participant
- RCTs of Qili Qiangxin capsule for patients with DCM were strictly included and were not restricted by the publishing language. Specific and accurate data can be obtained for analysis. All subjects meet the relevant diagnostic criteria for DCM established by the American Heart Association or the Chinese Medical Association. Regardless of age, gender, race, and region. Exclusion Criteria. The research that is not rigorous, the data that is incomplete or has a significant error, and the statistical analysis that cannot be performed were excluded. The study on the treatment group or control group with other Chinese herbal medicine, the animal experiments, experience reports, conference papers, and the repeated published literature which could not get the full text were excluded.
- Animal
- Human Disease Modelled
- Intervention
- The intervention group received conventional treatment combined with Shexiang Baoxin Pill (produced by Shijiazhuang Yiling Pharmaceutical Co., Ltd, oral administration, 4 pills at a time, three times a day).
- Comparator Control
- The control group received conventional treatment including antiplatelet aggregation drugs, calcium channel blockers-receptor blockers, angiotensin-converting enzyme inhibitors, statins, nitrates, and nicorandil.
- Main Outcome
- Clinical efficiency of cardiac function Measures of effect The relative risk (RR) was used for the effect measure of main outcomes.
- Outcome Measure
- Additional Outcome
- left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVDD), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), Tumor necrosis factor alpha(TNF-α). Measures of effect The mean difference (MD) was used for the effect measure of additional outcomes.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Cardiomyopathy, Dilated; Drugs, Chinese Herbal; Heart Failure; Humans; qiangxin
- Contact
- Jingjing Wei [email protected]
- Organisational Affiliation
- Henan University of Traditional Chinese Medicine
- Funding Source
- This study was supported by the Ministry of Science and Technology of the People’s Republic of China’s Key Projects during the 13th Five-Year Plan Period (no.#2019YFC1710003) and the Chinese Medicine Evidence-Based Capacity Building Project of the State Administration of Traditional Chinese Medicine (2019XZZX-XXG003).
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-13
- Registration Date
- 2022-01-12
- Anticipated Start Date
- 2021-12-30
- Anticipated Completion Date
- 2022-03-01
- Title Cn
- 芪苈强心胶囊治疗扩张型心肌病的有效性和安全性：一项系统评价与Meta分析
- Title En
- Efficacy and Safety of Qili Qiangxin capsule for dilated cardiomyopathy: A Systematic Review and Meta-Analysis
- Bilingual Status
- complete